Please login to the form below
Xigduo
This page shows the latest Xigduo news and features for those working in and with pharma, biotech and healthcare.
J&J's Invokana receives new FDA safety warning
However the FDA said in a statement: “We are continuing to evaluate the risk of bone fractures with other drugs in the SGLT2 inhibitor class, including dapaglifozin (Farxia, Xigduo XR) and
Latest news
-
FDA clears Jardiance combo for type 2 diabetes
Johnson &Johnson's Invokamet (canagliflozin plus metformin) and AstraZeneca's Xigduo (dapagliflozin and metformin) already have marketing clearance in the US, getting the nod last year.
-
NICE wants more data on Boehringer’s Jardiance
summer. Both drugs area already making headway in the UK due in part to their potential in combination therapies, and AZ has even launched the combination pill Xigduo in the UK.
-
FDA approves J&J’s diabetes combo
Invokamet is the first combination of this kind to win FDA approval, putting it ahead of competition from AstraZeneca (AZ) and Xigduo, which combines its SGLT-2 inhibitor Forxiga (dapagliflozin) and ... This drug was the second SGLT-2/metformin
-
Boehringer/Lilly's Jardiance approved in US
Both these products are also available as combination treatments with metformin in versions called Vokanamet (Invokana and metformin) and Xigduo (Forxiga and metformin).
-
NICE backs Janssen’s once-daily diabetes drug
a Forxiga/metformin combination in the form of Xigduo.
More from news
Approximately 3 fully matching, plus 9 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- My journey advancing the science in pulmonary hypertension
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- A new era for UK-Japanese scientific research relations
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- New Omicron sub-variants cause COVID-19 cases to rise in the UK
- Novartis announces positive phase 3 trial results for advanced oesophageal cancer
- Sanofi Global Health unveils new nonprofit Impact brand
- Pfizer announces commitment to achieve Net-Zero Standard by 2040
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- A creative awakening – how pharma is bringing innovation to the patient journey
- Behaviour change – a maze of decisions influenced by personal habits, experiences and intentions
- My journey advancing the science in pulmonary hypertension
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- Novartis publishes final positive phase 3 results of Zolgensma in Nature Medicine
- Delivering content to fuel omnichannel engagement
PMHub
Madmicrobe Studios - Medical Animation
MadMicrobe is an award-winning team of certified medical illustrators creating animations that engage your audience with immersive experiences that bring...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
